+ 86 (1812) 4514114 info@phcoker.com

I-Avanafil powder emfutshane (330784-47-9)

I-Avanafil powder isetyenziselwa ukunyanga amadoda anokungasebenzi kakuhle (okwabizwa ngokuba kukungabi nazinto zesondo). I-Avanafil yeqela le …………… ..


Isimo: KwiMveliso yoLuntu
Iyunithi: 25kg / Drum
Amandla: 1290kg / inyanga

inkcazelo

I-Avanafil powder emfutshane (330784-47-9) ividiyo

I-Avanafil powder emfutshane (330784-47-9) Inkcazo

I-Raw Avanafil powder yi-PDE5 inhibitor evunyiweyo yokungasebenzi (i-ED: ukungabi namandla; ukungakwazi ukufumana okanye ukugcina i-erection emadodeni). I-Raw Avanafil powder isebenza ngokuthintela uhlobo oluthile lwe-phosphodiesterase ye-5 enzyme efumaneka kwizicubu ezahlukeneyo zomzimba, kodwa ngokuyintloko kwi-penus cavernosum penis, nakwi-retina. Isebenza ngokwandisa ukuphuma kwegazi kwilungu lobudenge ngexesha lokuvuselela ngokwesondo. Amanye amachiza afanayo yi-sildenafil, tadalafil kunye ne-vardenafil. Uncedo lwe-Raw Avanafil powder kukuba unokuqala ngokukhawuleza kwesenzo xa kuthelekiswa nezinye i-PDE5 inhibitors. Ifunwa ngokukhawuleza, ifikelela ekugxininisweni okukhulu malunga nemizuzu ye-30-45.Ngaphaya kwesibini kwisithathu sabathathi-nxaxheba babenakho ukwenza isenzo sesondo ngaphakathi kwemizuzu ye-15.

I-Avanafil powder emfutshane (330784-47-9) Suqobo

Igama lemveliso Avanafil powder
Igama leKhemikhali 330784-47-9;STENDRA; (s)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790; TA-1790
uhlobo Numama Stendra kunye neSpedra
Iqela leziyobisi PDE5 inhibitor
Inani leCAS 330784-47-9
InChIKey WEAJZXNPAWBCOA-INIZCTEOSA-N
I molecular Fi-ormula C23H26ClN7O3
I molecular WSibhozo 483.95
IMasaisotopic Mass 483.179 g / mol
Ukuxuba Point 150-152 ° C
Fukuhlaziywa kwakhona Point Akukho datha ekhoyo
I-Biological Half-Life Kuthetha ukuthatha isigxina-ubomi = 5.36 - ii-10.66 iiyure
Kubonakala Powder
Sukufaneleka DMSO, iMethanol
Sisibetho Tukushisa Gcina kwi-4 ° C
isicelo I-phosphodiesterase (PDE5) inhibitor, esetyenziselwa ukunyanga ukungasebenzi kakuhle.

I-Avanafil powder emfutshane (330784-47-9) Inkcazo

I-Avanafil isetyenziselwa ukunyanga ukungasebenzi kakuhle (i-ED: ukungabi namandla; ukungakwazi ukufumana okanye ukugcina i-erection emadodeni). I-Avanafil powder ikwisigaba samayeza abizwa ngokuba yi-phosphodiesterase (PDE) inhibitors. Isebenza ngokwandisa ukuphuma kwegazi kwilungu lobudenge ngexesha lokuvuselela ngokwesondo. Ukuhamba kwegazi okwandisiweyo kunokubangela ukubakho. I-Avanafil powder ayiphilisi ukungasebenzi okanye ukwandisa umnqweno wesondo. I-Avanafil ayikuthinteli ukukhulelwa okanye ukwanda kwezifo ezosulela ngokwabelana ngesondo njengegciwane lesifo somzimba sokugonywa (i-HIV).

I-Avanafil powder (330784-47-9) Indlela yokuSebenza

I-Avanafil yinto ekhethiweyo ye-phosphodiesterase 5 (PDE5) inhibitor esetyenziselwa ukunyanga ukungasebenzi kakuhle okubangelwa sisifo seswekile, ukubudala bexinzelelo lwe-oxidative okanye ezinye iingxaki. I-Avanafil ithintela i-cGMP ye-phosphodiesterase yohlobo oluthile lwe-5 (PDE5) enoxanduva lokudodobala kwe-cGMP kwindawo ye-corpus cavernosum ebekwe ecaleni kwempundu. I-penile erection ngexesha lokuvuselela ngokwesondo kubangelwa kukunyuka kwegazi le penile okubangelwa kukuphumla kwemithambo ye-penile kunye ne-corpus cavernosal message egudileyo. Le mpendulo iphakathi kukukhutshwa kwe-nitric oxide (NO) kwizitishi ze-nerve kunye neeseli ze-endothelial, ezivuselela ukudalwa kwe-cGMP kwiiseli zemisipha egudileyo. I-cyclic GMP ibangela ukuphumla kwemisipha egudileyo kunye nokunyuka kokuhamba kwegazi ukungena kwi-corpus cavernosum. Inhibition yohlobo lwe-phosphodiesterase 5 (PDE5) yi-avanafil iphucula umsebenzi ngokwandisa inani le-cGMP.

Ukusetyenziswa kwe-Avanafil powder (330784-47-9)

I-Avanafil powder isetyenziselwa ukunyanga amadoda anokungasebenzi kakuhle (okwabizwa ngokuba kukungabi nazinto zesondo).

Iphakanyisiwe i-Avanafil powder (330784-47-9) Isisombululo

Kwabaninzi abantu, i-dose yokuqala ephakanyisiweyo ye-avanafil powder yi-100 mg ngosuku ithathwa malunga nemizuzu eyi-30 ngaphambi kokusebenza ngokwesondo. Ngokuxhomekeke kwanele ngokwampendulo okanye kwimiphumo emibi, umthamo unganyuswa kwi-200 mg okanye wehla kwi-50 mg ngosuku. Abantu abathi bathabatha amayeza anokwandisa amanqanaba egazi ka-avanafil akufanele angadluli umthamo we-50 mg kwiiyure ze-24 (Jonga ukusebenzisana kwezidakamizwa).

Iinzuzo ze-Avanafil powder (330784-47-9)

Yeka ukusebenzisa i-avanafil uze ubize ugqirha wakho kanye xa unayo:

▪ utshintsho lombono, ukulahleka kombono ngokukhawuleza

▪ ukukhala ezindlebeni zakho, okanye ukulahlekelwa kwintetho ngokukhawuleza;

▪ ubuhlungu, ukuvuvukala, ukufudumala, okanye ubomvu kwelinye okanye emilenzeni yomibini;

▪ ukuphefumula, ukuvuvukala ezandleni okanye ezinyaweni;

▪ inzwa ehamba ngokukhanya, njengokuba ungadlula; okanye

▪ i-penis erection ebuhlungu okanye ihlala iiyure ze-4 okanye ngaphezulu.

Iziphumo eziqhelekileyo ziquka:

▪ intloko;

▪ ukutshisa (ukufudumala, ubomvu, okanye ukuvakalelwa);

▪ iimpawu ezibandayo ezifana neempuphu okanye impumlo epholileyo, emqaleni; okanye

▪ intlungu.


=

Iziqulatho kunye nokuqulunqwa kwemveliso

Imibuzo ye-9 ukuzibuza ngaphambi kokuthatha i-Avanafil

Ucaphulo

  1. URyan M Burke, uJeffery D Evans, i-Avanafil kunyango lwe-dysfunction: uphononongo lwayo, i-Vasc Health Risk Manag. I-2012; I-8: 517-523.
  2. DeRogatis LR, uBurnett AL. I-epidemiology yeentsholongwane zesondo. J Sex Med. 2008; 5: 289-300.
  3. UZhao C, uKim S, uYan D, et al. Ukusebenza ngokukhuselekileyo kunye nokukhuseleka kwe-avanafil yokunyanga ukungasebenzi kakuhle: iziphumo zokumiliselwa ngobuninzi, ukungakhethi, ukungaboni kabini, ukulawulwa kwe-placebo. BJU Int. I-2012 Mar 27;

I-Shangke Chemical yinkampani ephakamileyo yezobuchwepheshe echanekileyo kuma-intermediate asebenzayo (APIs). Ukulawula umgangatho ngexesha lokuvelisa, inani elikhulu labaqeqeshi abanolwazi, izixhobo zokuvelisa iikholeji zokuqala kunye nama-laboratories ngamanqaku aphambili.

Qhagamshelana nathi